Studies on combinations of blood-based Aβ42/Aβ40, P-tau and NfL have reported findings on their diagnostic accuracy for the separation of AD dementia from CU individuals and patients with non-AD disorders7,9,11,19–22, but data are lacking on their performance in predicting cognitive decline and clinical progression in CU individuals. The gene discussed is MAPT; the disease is Alzheimer disease.